Terazosin and doxazosin in the treatment of BPH: Results of a randomized study with crossover in non-responders

Urologia Internationalis

Volumn 73, Issue 2, 2004, Pages 125-129

  Samli, M Murat ^a,b   Dincel, Cetin ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b Cumhuriyet mah Cizmeci Vehbi sk   (Turkey)

Author keywords

Benign prostatic hyperplasia; Doxazosin; Drug switch; Terazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TERAZOSIN;

ADULT; AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; ASTHENIA; BLADDER CONTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; EVALUATION; FOLLOW UP; HEADACHE; HUMAN; MALE; NIGHT; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CROSS-OVER STUDIES; DOXAZOSIN; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA;

EID: 8344242307     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079692     Document Type: Article

References (29)

1. Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47:193-202.
2. Lepor H, Meretyk S, Knapp-Maloney G: The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol 1992;147:1554-1557.
3. 1- adrenoceptors in the prostate adenoma and prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991;67:493-498.
4. Shapiro E, Hartanto V, Lepor H: The response to α-blockade in benign prostatic hyperplasia is related to the percent area density of prostatic smooth muscle. Prostate 1992;21:297-307.
5. 1-adrenoceptors using radioligand receptor binding on slide mounted tissue section. J Urol 1993;150:2002-2026.
6. Kunishima Y, Kawabe K, Niijima T: A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J Urol 1985;134:396-398.
7. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
8. 1-adrenoceptor antagonists. Eur Urol 1999;36(suppl):48.
9. Hayduk K, Schneider HT: Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. Am J Cardiol 1987;59:95G-98G.
10. Jansen DJ Jr, Resch ND, Hoffman RM: Doxazosin-to-terazosin switch for benign prostatic hyperplasia. Am J Health Syst Pharm 1999;56:1351.
11. Cockett ATK, Aso Y, Chatelain C: Recommendations of the international consensus committee; in Cockett ATK, Aso Y, Chatelain C (eds): The Second International Consultation of Benign Prostatic Hyperplasia. Paris, Pitié Salpêtrière, 1993, pp 533-564.
12. Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds): The Fourth International Consultation on Benign Prostatic Hyperplasia, Paris, July 2-5, 1997. Plymouth, Health Publication Ltd, 1998, pp 63-81.
13. Akduman B, Crawford ED: Terazosin, doxazosin, and prazosin: Current clinical experience. Urology 2001;58(suppl 1):49-54.
14. Lepor H, Laddu A: Terazosin in the treatment of benign prostatic hyperplasia: The United States experience. Br J Urol 1992;70(suppl 1):2-9.
15. Debruyne FM: Alpha blockers: Are all created equal? Urology 2000;56(suppl 1):20-22.
16. MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE: A randomized double-blind study assessing 4 vs. 8 mg doxazosin for benign prostatic hyperplasia. J Urol 1999;162:1629-1632.
17. Kaplan SA: Uroselective α-blockade for benign prostatic hyperplasia: Clinically significant or marketing savvy? Urology 1999;54:776-779.
18. Fawzy A, Vashi V, Chung M, Dias N, Gaffney M: Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. Urology 1999;53:329-335.
19. Mobley DF, Kaplan S, Ice K, Gaffney M, Dias N: Effect of doxazosin on the symptoms of benign prostatic hyperplasia: Results from three double-blind placebo-controlled studies. Int J Clin Pract 1997;51:282-288.
20. Kaplan SA, Soldo KA, Olsson CA: Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995;28:223-228.
21. Kirby RS: A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91:41-44.
22. Kaplan SA, Te AE, Ikeguchi E, Santarosa RP: The treatment of benign prostatic hyperplasia with α-blockers in men over the age of 80 years. Br J Urol 1997;80:875-879.
23. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995;45:406-413.
24. McKiernan JM, Lowe FC: Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J 1997;90:509-513.
25. Mikhailidis DP, Khan MA, Milionis HJ, Morgan RJ: The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000;16(suppl 1):31-36.
26. 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1990;144:1393-1398.
27. Uygur MC, Gur E, Arik AI, Altug U, Erol D: Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study. Andrologia 1998;30:5-10.
28. Gillenwater JY, Fawzy A, Klimberg I: For the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind placebo-controlled, dose-response multicenter study. J Urol 1995;154:110-115.
29. 1- blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993;24:319-326.